Teva Announces Strategic Collaboration with Klinge Biopharma and Formycon for Commercializing Biosimilar Candidate to Eylea in Europe and Israel
Teva Announces Strategic Collaboration with Klinge Biopharma and Formycon for Commercializing Biosimilar Candidate to Eylea in Europe and Israel
01/13/25, 6:02 AM
Location
tel avivIndustry
pharmaceutical
biotechnology
health care
manufacturing
Type
partnership
Teva Pharmaceuticals International GmbH has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea (aflibercept) in Europe, excluding Italy, and in Israel. This collaboration aims to leverage Teva's commercial experience, distribution network, and sales and marketing reach across Europe with Formycon's capabilities in biosimilar medicine development.
Company Info
Location
tel aviv, tel aviv district, israel
Additional Info
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative medicines research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products.